Home  >  News
Biotechnology + Font Resize -

Sinovac Biotech gets positive decision from WHO on its hepatitis A vaccine, Healive

Beijing
Friday, December 29, 2017, 12:00 Hrs  [IST]

Sinovac Biotech, a leading provider of biopharmaceutical products in China, announced that it has received a positive decision from the World Health Organization (WHO) on the acceptability, in principle, of its Healive, a hepatitis A vaccine product, for purchase by United Nations (UN) agencies. The company’s Healive product was assessed according to the WHO Prequalification Procedure.

Weidong Yin, chairman, president and CEO of the company, commented that “I am very pleased that Healive has passed the assessment under WHO Prequalification procedures. This is an important milestone for Sinovac which we expect will provide opportunities to supply this vaccine to respective UN agencies as well as accelerate the regulatory approval process for this vaccine in international countries outside China.”  

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |